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Abstract
Purpose: As imaging of the cell surface tetraspan protein epithelial membrane protein-2 (EMP2)
expression in malignant tumors may provide important prognostic and predictive diagnostic
information, the goal of this study is to determine if antibody fragments to EMP2 may be useful
for imaging EMP2 positive tumors.
Procedures: The normal tissue distribution of EMP2 protein expression was evaluated by
immunohistochemistry and found to be discretely expressed in both mouse and human tissues.
To detect EMP2 in tumors, a recombinant human anti-EMP2 minibody (scFv-hinge-CH3 dimer;
80 kDa) was designed to recognize a common epitope in mice and humans and characterized.
In human tumor cell lines, the antibody binding induced EMP2 internalization and degradation,
prompting the need for a residualizing imaging strategy. Following conjugation to DOTA
(1,4,7,10-tetraazacyclododecane-N,N′,N′,N′″-tetraacetic acid), the minibody was radiolabeled
with 64Cu (t1/2012.7 h) and evaluated in mice as a positron emission tomography (PET) imaging
agent for human EMP2-expressing endometrial tumor xenografts.
Results: The residualizing agent, 64Cu-DOTA anti-EMP2 minibody, achieved high uptake in
endometrial cancer xenografts overexpressing EMP2 (10.2±2.6, percent injected dose per gram
(%ID/g) ± SD) with moderate uptake in wild-type HEC1A tumors (6.0±0.1). In both cases,
precise tumor delineation was observed from the PET images. In contrast, low uptake was
observed with anti-EMP2 minibodies in EMP2-negative tumors (1.9±0.5).
Conclusions: This new immune-PET agent may be useful for preclinical assessment of anti-
EMP2 targeting in vivo. It may also have value for imaging of tumor localization and therapeutic
response in patients with EMP2-positive malignancies.
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Introduction
Apromising avenue in molecular imaging is the developmentof agents that detect the presence and levels of molecular
biomarkers in malignant tumors. In this way, molecular
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imaging may provide important information for patient
stratification to targeted therapies, aid in restaging
diseases, and be used to monitor treatment response. Thus,
new biomarkers that may aid in patient management are
urgently needed.
Epithelial membrane protein-2 (EMP2) is a novel
oncogene upregulated in a number of gynecological tumors.
A member of the growth arrest specifϊc-3/peripheral myelin
protein-22 (GAS3/PMP22) family of tetraspan proteins,
overexpression of EMP2 is associated with tumor progres-
sion as well as poor patient survival [1, 2]. Its expression is
detected in up to 60 % of endometrial tumors and 75 % of
advanced ovarian tumors [1–3].
Functionally, EMP2 appears to be important for traffick-
ing, intracellular compartmentalization, and the surface
display of selected receptors and glycolipids [4]. EMP2
physically associates with and regulates the activity of
integrin-FAK signaling complexes, with the consequence
that high levels of EMP2 increase tumor cell invasion [5–8].
These findings, concordant with the role of other members
of the tetraspan family, indicate that EMP2 organizes
molecules at the cell surface that are brought into engage-
ment with specific signaling complexes, therefore control-
ling downstream biological responses [9–12].
We have previously reported an anti-EMP2 diabody
(scFv dimer; 55 kDa) derived from a human immunoglob-
ulin V-gene phage display library that recognizes a shared
epitope on murine and human EMP2 [13]. Localized
treatment with the anti-EMP2 diabody showed therapeutic
efficacy with reduced tumor load in xenograft models for
endometrial and ovarian tumors. Given that EMP2 over-
expression plays an important role in aggressive tumor
behavior and poor clinical outcome [1], early stage detection
and quantification of EMP2 may be clinically relevant and
used for selection of optimal therapy for individual patients.
Positron emission tomography (PET) imaging is a widely
used imaging modality due to its higher image resolution
and sensitivity compared to single-photon imaging [14]. In
oncology, PET most commonly employs 2-deoxy-2-[18F]
fluoro-D-glucose ([18F]FDG) as a tracer for imaging elevated
metabolism in tumors [15]. However, [18F]-FDG has certain
limitations in tumor detection. First, it is not specific for
tumor detection, as inflammation and wound healing also
exhibit tissue uptake of [18F]-FDG [16]. Second, with regard
to gynecological tumors, [18F]-FDG uptake is deficient in a
substantial fraction of gynecologic malignancies and can be
insensitive for assessing responses to certain antitumor
therapies [17–19].
Here, we have generated a larger anti-EMP2 antibody
fragment, a minibody (scFv-hinge-CH3 dimer; 80 kDa). In
order to determine if EMP2 could be detected in vivo, the
minibody was conjugated to DOTA and radiometal labeled
with the positron emitter 64Cu (T1/2012.7 h). Small animal
PET imaging showed excellent tumor targeting of the 64Cu-
DOTA-minibody in mice bearing EMP2 positive endome-
trial tumor xenografts. Thus, whole-body PET detection of
this anti-EMP2 antibody fragment may have promise as a
potential imaging agent for staging and monitoring of
EMP2-positive endometrial tumors.
Materials and Methods
Cell Lines and Cell Culture
HEC1A/EMP2 cells were generated by stable transfection with the
EGFP-N3 expression vector bearing human EMP2 as previously
described [7]. Ramos cells were purchased from American Type
Culture Collection (ATCC, Manassas, VA, USA), and the murine
mammary tumor D2F2 was kindly provided by Dr. Manuel
Penichet (UCLA). The cells were cultivated at 37 °C in a
humidified 5 % CO2 in DMEM medium (Mediatech, Manassas,
VA, USA) supplemented with 10 % fetal calf serum (Hyclone
Laboratories, Logan, UT, USA), 2 mM L-glutamine, 1 mM sodium
pyruvate, 100 U/ml penicillin, and 100 U/ml streptomycin (all from
Invitrogen Life Technologies, Carlsbad, CA, USA).
Institutional Review
All procedures with and tissue procurement from mice were
performed under Institutional Review Board (IRB) approval. All
human samples were obtained from the UCLA Department of
Pathology and Laboratory Medicine under Institutional Review
Board exemption approval.
Construction and Production of Anti-EMP2
Antibody Fragments
The anti-EMP2 minibody was generated using published methods
[20]. Briefly, genes encoding the variable KS83 domain were
assembled by PCR into a single-chain Fv fragments (scFv) [13] and
cloned into pCR2.1-TOPO vector (Invitrogen). The genes encoding
the human IgG1 hinge and CH3 domain (hinge-CH3) were also
assembled by PCR and cloned into another pCR2.1-TOPO vector.
The pCR2.1-TOPO-scFv and scFv-hinge-CH3 were digested and
inserted into the pcDNA3.1myc/his(−) mammalian expression
vector (Invitrogen) at XbaI and EcoRI site and XhoI and EcoRI,
respectively. The resultant anti-EMP2 minibody was termed KS83.
Chinese hamster cells (CHO-K1) were transfected with 30 μg of
linearized pcDNA3.1-KS83 vector DNA and selected using 1 mg/ml
of geneticin (G418, Sigma-Aldrich, St. Louis, MO, USA) as
described previously [21]. After approximately 2 weeks, cells were
screened for expression by enzyme-linked immunosorbent assay
(ELISA) using goat anti-human Fc-specific antibody (Jackson
Immunoresearch, West Grove, PA, USA). The highest producers
were identified, and the cells were subcloned through serial
dilutions to isolate individual clones. Cells from high expressing
individual clones were expanded in Celline AD 1000 bioreactor
flasks (IBS Integra Biosciences, Hudson, NH, USA) according to
the manufacturer’s instructions. The KS83 minibody was purified
from supernatant by Protein-L affinity chromatography (Thermo
Fisher Scientific Inc., Rockford, IL, USA), using phosphate-
buffered saline (PBS) as running buffer. The elution buffer was
using 30 % 0.2 M citrate buffer (pH 2.1) in PBS into 80 % v/v
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1 M Tris base, pH 8.2. Purified minibody was dialyzed against
PBS and concentrated using Amicon Ultra-4 (Millipore, Billerica,
MA, USA). The final concentration of purified minibodies was
determined by a Nanodrop 2000 (Thermo Scientific).
Enzyme-linked immunosorbent assay
The anti-EMP2 antibody fragments were captured by the peptides
corresponding to the extracellular loop of human EMP2 [13], and
ELISA was performed as described previously [13]. Specifically,
bound minibodies were detected with horseradish peroxidase
(HRP)-conjugated goat antihuman Fc-specific antibody (Jackson
Immunoresearch), followed by tetramethylbenzidine solution
(eBioscience, San Diego, CA, USA). Plates were read using a
Model 550 microplate reader (Bio-Rad, Hercules, CA, USA) at
450 nm.
Flow Cytometry
HEC1A/EMP2 cells (1×106), murine D2F2 cells, or Ramos cells
suspended in 1 ml of flow buffer (PBS, 0.2 % bovine serum
albumin, and 0.02 % sodium azide), were centrifuged for 5 min at
500×g, 4 °C. Cells were resuspended in 0.1 ml flow buffer and
incubated with 0.5 μg of the primary antibody for 1 h at 4 °C on a
rotator. Cells were washed three times with flow buffer and
incubated for 30 min at 4 °C with phycoerythrin (PE)-conjugated
goat antihuman Fc-specific antibody (Jackson Immunoresearch) in
0.1 ml flow buffer. Following three washes, cells were resus-
pended in 0.4 ml flow buffer, and flow cytometry was immediately
performed. Fc receptors on Ramos cells were blocked by
incubation for 15 min with 50 μl Fc block solution (heat
inactivated rabbit normal serum, 1:10 dilute in PBS, freeze–thaw
five cycles).
Immunohistochemistry
Mouse and human tissues were stained for EMP2 expression as
previously described [22]. Normal human tissue were stained using
an array created by the immunohistochemistry core of the
Translational Pathology Core Laboratory. This array contains 248
spots from 30 tissues with examples of every type from at least two
patients, and all samples were verified as being normal by
histology. All positive staining was verified independently using
additional full tissue sections from two additional patients. For
mouse tissue, organs were extracted, tissue fixed in 10 % formalin,
embedded in paraffin, and sectioned at 5-μm thickness. To assess
EMP2 expression in all tissue, antigen retrieval was performed
using 0.1 M citrate buffer (pH 6.0) at 95 °C for 20 min. The
slides were incubated with rabbit antimouse EMP2 antisera
(1:250) [23], antihuman EMP2 antisera (1:800) [1] or control
rabbit serum at the same dilutions overnight. The antibody signal
was visualized using the Vectastain ABC kit (Vector Labs,
Burlingame, CA, USA) according to the manufacturer’s instruc-
tions. EMP2 expression was detected using diaminobenzidine,
and nuclei were counterstained using hematoxylin. Semiquantita-
tive scoring of the EMP2-stained tissue was conducted using a
0–3 intensity scale.
Western Blot Analysis
Mouse tissues were processed using fresh specimens and immedi-
ately frozen on dry ice. Frozen human tissue samples of
postdiagnostic remnant surgical resection specimens obtained from
the UCLA Department of Pathology and Laboratory Medicine.
Tissues were homogenized using cold radioimmunoprecipitation
assay buffer and then resuspended in Laemmli buffer. To detect
EMP2 expression, cell extracts were treated with peptide N-
glycosidase F (New England Biolabs, Beverly, MA, USA) to
deglycosylate the proteins. The lysates were separated on a 12 %
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) gel, and proteins were transferred onto nitrocellulose (Bio-
Rad Laboratories, Hercules, CA, USA). EMP2 was detected using
rabbit antihuman EMP2 (1:2000) antiserum followed by a HRP-
conjugated goat antirabbit IgG and enhanced chemiluminescence
detection reagents (GE Healthcare, Piscataway, NJ, USA).
Immunofluorescence
HEC1A/EMP2 cells were plated onto glass coverslips (Fisher
Scientific, Pittsburgh, PA, USA). Cells were washed in PBS and
then incubated at various time points with 20 μg/ml of the control
A10 or the anti-EMP2 diabody. To visualize the diabody, cells
were fixed in 1.6 % formaldehyde for 20 min followed by
incubation with a fluorescein isothiocyanate-conjugated anti-Myc
antibody (Invitrogen). To visualize EMP2 staining, cells were fixed
and permeabilized in methanol at −20 °C for 30 min and rehydrated
in PBS. Cells were blocked in 1 % normal goat serum for 45 min
and incubated overnight at 4 °C with rabbit antihuman EMP2
antisera (1:400) in a humidified chamber. Cells were rinsed with
PBS/0.01 % Triton X-100 and then incubated (2–4 h at room
temperature) with rhodamine-conjugated goat antirabbit IgG
(1:4,000; Jackson Immunoresearch). Negative controls included
incubation of cells with secondary antibody alone. Cells were
copiously washed in PBS/0.01 % Triton X-100, rinsed briefly with
double deionized H2O, and mounted in Vectamount HardSet with
4′,6-diamidino-2-phenylindole solution. Images were taken using
an Olympus BX51 light microscope coupled with the DP72 digital
camera at 400× magnification.
DOTA Conjugation and Radiolabeling with 64Cu
The KS83 minibody was conjugated with 1,4,7,10-tetraazacyclo-
dodecaneN,N′,N″,N′″-tetraacetic acid mono-N-hydroxysuccinimide
ester (DOTA-NHS-ester; Macrocyclics, Dallas, TX, USA) accord-
ing to the method described previously [24]. Different conjugation
molar ratios of DOTA to minibody (20, 50, 100, and 1,000) were
used in order to determine the condition that would preserve the
binding activity of the conjugate. 64Cu (copper chloride in 0.1 M
HCl; radionuclide purity, 999 %) was provided by the
Mallinckrodt Institute of Radiology (Washington University
School of Medicine). For radiometal labeling, 200 μg of
DOTA-conjugated KS83 was incubated with 400 μCi
(14.8 MBq) of 64Cu in 0.1 M NH4 citrate (pH 5.5) for
50 min at 43 °C. The radiolabeling efficiency was determined
using instant thin-layer chromatography with Tec-Control Chro-
matography strips according to the manufacturer’s instruction
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(Biodex Medical Systems, Shirley, NY, USA). In some experi-
ments, the anti-CD20 minibody was used as a negative control
isotype tracer [25]. DOTA conjugation and radiolabeling with
64Cu were performed in the same way as above.
Immunoreactivity of Radiolabeled Minibody
Immunoreactivity was measured as previously described [21].
In this study, HEC1A/EMP2 cells (6–9×107) in excess were
incubated with 20 ng of 64Cu-DOTA-KS83 for 1 h on ice.
Cells were centrifuged at 1,000×g for 5 min, and the activity
remaining in the supernatant was counted using a Wallac
WIZARD automatic γ-counter (Perkin-Elmer Life and Analytic
Sciences Inc., Waltham, MA, USA). The immunoreactivity
(%IR) of the radiolabeled antibody was calculated with the
following formula: %IR ¼ 100  activity from the tubes withð
cells activity from control tubes without cells 100Þ.
Tumor Xenograft Murine Model
All procedures involving animals were performed under
approved protocols of the UCLA Animal Research Commit-
tee. Six to 8-week-old female BALB/c nude mice (Charles
River Labs, Wilmington, MA, USA) were injected subcuta-
neously in the shoulder with 1×105 of HEC1A/EMP2 or wild-
type HEC1A cells 3–4 weeks prior to imaging. 5×106 Ramos
cells were injected to form the subcutaneous tumor 1–2 weeks
prior to imaging. Each group utilized five mice per
experiment.
Small-Animal PET Imaging
Mice were anesthetized with 2 % isoflurane prior to intrave-
nous injection of ~100 μCi (3.7 MBq) of 64Cu-DOTA-KS83
minibody (50 μg) or 64Cu-DOTA-CD20 minibody (50 μg) via
tail vein (specific activity, 0.074 MBq/μg). Mice were imaged
at 4 and 20 h post-injection. A cylinder of known weight,
containing a known amount of radioactivity, was scanned to
provide a calibration standard. Mice were serially imaged using
the micro-PET Focus 220 PET Scanner (Siemens Preclinical
Solutions, Knoxville, TN, USA). To enable imaging, mice were
positioned in a prone position along the long axis of the
microPET scanner and imaged. Images were reconstructed
using a filtered backprojection reconstruction algorithm [26].
Directly after the final microPET scan, a CT scan was
performed using a MicroCAT II Scanner (Concorde Micro-
systems, Knoxville, TN, USA).
Biodistribution and ROI Analysis
After the final imaging scan, the mice were euthanized, major
organs and tumors were removed and weighed, and radioactivity
was counted using a Wallac WIZARD automatic γ-counter (Perkin-
Elmer Life and Analytic Sciences Inc.). The percent injected dose
per gram of tissue (%ID/g) was calculated to represent the
radioactivity uptake in tumor and organs and decay corrected.
AMIDE was used to analyze overlaid CT and PET scans [27].
Regions of interest (ROIs) were drawn based on the CT image. ROI
statistics were generated using AMIDE and converted to percent
injected dose per gram after input of the individual decay corrected
dose and cylinder calibration factor.
Statistical Analysis
All significant differences between groups were evaluated using
two-tailed Student’s unpaired t test or ANOVA at a 95 %
confidence level (GraphPad Prism version 3.0; GraphPad Software,
La Jolla, CA, USA), and PG0.05 were considered significant.
Results
Expression of the EMP2 Protein
To determine the suitability of EMP2 as a new molecular
imaging target, its tissue expression in mouse and human
was evaluated (Fig. 1). Western blot of mouse tissue lysates
Fig. 1. Biodistribution and expression of the EMP2 protein.
a Mouse tissue lysates were probed for EMP2 expression.
The ejaculatory ducts include regions from the epididymis
and vas deferens. Arrow depicts deglycosylated EMP2
(18 kD). b Immunohistochemistry analysis of mouse organs.
The organs are designated as follows: A kidney, B epididy-
mis, C lung, D liver, E heart, F spleen, G brain, H jejunum. c
Immunohistochemistry analysis of human organs. The rep-
resentative organs are designated as follows: A lung, B
spleen, C endometrial tumor, D isotype control in the lung.
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revealed high expression of EMP2 in the lung, and some
expression in vas deferens (Fig. 1a). Immunohistochemistry
confirmed EMP2 expression in the epididymis and lung
(panels B and C) and no expression in the kidney, liver,
heart, spleen, brain, and jejunum (Fig. 1b, panels A, D, E, F,
G, H, respectively). As there is a 76 % amino acid homology
between human and mouse EMP2 (GeneBank numbers
AAC51779.1 and AAK29076.1), we next evaluated the
expression of EMP2 in a human tissue array using anti-
EMP2 antisera [22]. Similar to previous reports, EMP2 was
highly expressed in alveolar epithelium of the lung [28, 29],
in the retinal pigmented epithelium in the eye [22], and
within secretory endometrium [23, 30], as well as in the
epithelia of the vagina and fallopian tube (Table 1). In
contrast, detailed immunohistochemical analysis revealed
that EMP2 was undetectable in many human tissues
including the small and large intestines, pancreas, liver,
spleen, and kidney. To confirm its expression in humans,
additional full section tissues were stained. EMP2 expres-
sion was readily detectable in the lung (Fig. 1c, panel A) but
not in the spleen (panel B). In addition, high levels of EMP2
are seen in representative example of endometrial adenocar-
cinoma (panel C). The protein expression of EMP2 in these
tissues appeared to be specific as no staining was observed
using preimmune sera (lung, panel D). The limited normal
tissue distribution of human EMP2 makes it an attractive
target and suggests its suitability as a molecular target for
immunoPET.
Characterization of Purified KS83 Minibody
Previous experience from our group has shown that the
optimum antibody fragment for imaging is an intermediate
sized antibody, termed a minibody (Fig. 2a). Minibodies
show prolonged serum residence (T1/2β06 h) compared with
a diabody (T1/2β02–4 h) [31] and have been used success-
fully in clinical trials to detect tumors prior to surgical
excision [32]. The KS83 diabody was modified to create a
minibody, and in accord with expectations, purified KS83
minibody formed a covalent homodimer with an estimated
molecular mass of 75 kDa under non-reducing conditions
(Fig. 2b). Under reducing conditions, the KS83 minibody
was dissociated into a monomer of approximately 40 kDa.
Size-exclusion chromatography also showed the formation
of a dimer with a protein retention time at 31.36 min
(average of two experiments), matching with the expected
size of the minibody (Fig. 2c [20]). The ability of the KS83
minibody to bind to EMP2 was assessed directly on the
HEC1A/EMP2 by flow cytometry. The KS83 minibody
demonstrated clear binding to the surface of HEC1A/EMP2
cells, and its affinity was similar to that observed for KS83
diabody (Fig. 2d). In contrast, the isotype control anti-CD20
minibody exhibited no binding to the EMP2-positive cells.
To confirm that the KS83 minibody recognized murine
EMP2, D2F2 mammary tumor cells were utilized. D2F2
cells have moderate surface expression of EMP2 (Fu and
Wadehra, unpublished data), which was detected by the
KS83 minibody (Fig. 2e). This effect seemed to be specific
as the anti-CD20 minibody showed no binding to D2f2 cells.
Furthermore, as shown in Fig. 2f, Ramos cells expressed
high levels of CD20, but no EMP2 expression was found on
the cells. These results indicate that the KS83 minibody
specifically binds to EMP2 and recognizes native EMP2
expressed on the surface of both murine and human cells.
EMP2 Internalizes Rapidly in the Presence
of Anti-EMP2 Fragments
Antibody binding to its receptor often leads to receptor
internalization [33, 34]. To determine if EMP2 internalizes
upon binding of an anti-EMP2 antibody fragment, light
microscopy of HEC1A/EMP2 cells incubated with the anti-
EMP2 KS83 diabody was performed using a fluorescein-
conjugated anti-Myc antibody. As seen in Fig. 3a, binding of
KS83 diabody to HEC1A/EMP2 cells occurred within
10 min and remained cell-associated for up to 1 h, but was
lost by 24 h. When the EMP2 levels in response to treatment
with the anti-EMP2 antibody fragment was monitored, the
EMP2 levels on the HEC1A/EMP2 cell surface were notably
reduced within 24 h relative to the negative control cells
treated with the A10 isotype control diabody (Fig. 3b).
These results suggested that binding of anti-EMP2 antibody
fragments leads to receptor internalization and degradation
of the antibody fragment.
DOTA-Conjugated KS83 Minibody and Binding
Analysis of Bioconjugates
Given the rapid internalization of antibody-bound EMP2, a
residualizing radiolabel strategy was employed to visualize
tumors in vivo. Residualizing radiolabels, such as radioactive
metals attached to a bifunctional chelator such as DOTA,
become trapped in the cells and are therefore retained within
the cell longer than non-residualizing radiolabels [35]. The
KS83 minibody was conjugated to DOTA and binding of
the immunoconjugate to EMP2 was evaluated by flow
cytometry (Fig. 4a, b). The conjugation conditions were
investigated at different molar ratios of DOTA to KS83
Table 1. Summary of EMP2 staining in a normal human tissue array
EMP2-positive tissue EMP2-negative tissue
Lung Parathyroid Thyroid Testes
Skin Adipose Liver Skeletal muscle
Fallopian tube Esophagus Stomach Small intestine
Placenta Colon Anal mucosa Gall bladder
Vagina Omentum Adrenal gland Pancreas
Uterus Spleen Thymus Parotid gland
Heart Kidney Bladder
Submandibular gland Reactive lymph node
72 M. Fu et al.: Feasibility of Imaging EMP2 in Endometrial Cancer
minibody in order to maximally preserve the binding to
EMP2 (Fig. 4a). The optimal ratio of DOTA to KS83
minibody was found to be 20:1, and the number of DOTA
per minibody (~3) was estimated based on the 20 lysines
residues present in the KS83 minibody. At this conjugation
ratio, binding activity was similar to that of the unconjugated
minibody (Fig. 4b). The EMP2-binding of the DOTA-
conjugated KS83 minibody was verified by ELISA using
EMP2 peptide-coated plates (Fig. 4c). Serial dilutions of
unconjugated KS83 and DOTA-conjugated KS83 minibody
revealed similar EC50 of 24 ng/ml (0.30 nM) and 29 ng/ml
(0.36 nM), respectively. Hence, the 20:1 DOTA to minibody
ratio was used in all subsequent conjugation reactions.
Small-Animal PET Imaging using Anti-EMP2
64Cu-DOTA-Conjugated KS83 Minibody
The DOTA-KS83 minibody was radiolabeled with 64Cu, and
tumor targeting was evaluated in mice bearing HEC1A/
EMP2, HEC1A, and Ramos (EMP2-negative) xenografts.
Although both wild-type HEC1A and HEC1A/EMP2 cells
were injected on the same day, the growth rates of these cells
differ in vivo [8]. The average weight of HEC1a/EMP2
xenografts was 158±50 while HEC1A wild-type tumors
were significantly smaller (26±11 mg). As a negative
control, Ramos cells were injected and imaged when they
reached 232±23 mg. The radiolabeling efficiency for
Fig. 2. Characterization of purified KS83 minibody. a Schematic representation of an intact antibody (150 kDa) and engineered
antibody fragments including diabody (scFv dimer, ~55 kDa) and minibody (scFv-hinge-CH3 dimer, ~80 kDa). b Coomassie blue
staining after SDS-PAGE of purified KS83 minibody under non-reducing (NR) and reducing conditions (R). Lane 3 Molecular
weight marker. c Size-exclusion chromatography of purified KS83 minibody on a Superdex 200 column. Retention time of the
sample was compared with appropriate molecular weight standards. d Flow cytometric analysis of HEC1A/EMP2 cells stained
with antibody fragments KS83 minibody (black line), KS83 diabody (gray line), or isotype control anti-CD20 minibody (tinted
black line) and A10 diabody (tinted gray line) and detected by phycoerythrin-conjugated goat antihuman Fc-specific antibody. e
Flow cytometric analysis of murine D2F2 cells stained with KS83 minibody (black line). Anti-CD20 minibody was used as the
isotype control (gray line) and detected as above. f Flow cytometric analysis of Ramos cells stained with anti-CD20 minibody
(black line). KS83 minibody was used as the isotype control (gray line) and detected as above.
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DOTA-KS83 minibody was 97 %, and the immunoreactiv-
ity, or the biologically active fraction is the 64Cu-DOTA-
KS83 minibody that still retains binding to the target, was
84 %. Decay-corrected coronal micro-PET images were
obtained at 4 and 20 h after intravenous injection with 64Cu-
DOTA-KS83 minibody (Fig. 5a).
At both time points, HEC1A/EMP2 and wild-type tumors
were clearly visualized, and a representative image at 20 h
showed strong uptake in HEC1A/EMP2 tumor (white ellipse).
As the HEC1A tumor is small, minimal uptake was visible in
this coronal layer, but uptake was observed within the
transverse profile (yellow ellipse) (Fig. 5a). In contrast, the
EMP2-negative Ramos tumor had low minibody uptake
(Fig. 5b). Radioactive uptake was also observed in the lung,
heart, liver, and kidney at 4 h post-injection, with high activity
persisting in the liver and kidney at 20 h post-injection.
Levels of radioactive uptake (%ID/g) at 4 and 20 h were
quantitated by both ROI analysis and biodistribution studies
(Table 2). At 4 h, ROI analysis showed significantly higher
radioactive uptake using the 64Cu-DOTA-KS83 minibody in
HEC1A/EMP2 tumors (7.6±1.2 %ID/g) relative to HEC1A
(5.6±0.7 %ID/g; PG0.05) and Ramos tumors (2.6±1.0 %ID/g;
PG0.001). HEC1A tumors also displayed significantly more
radioactive uptake compared with that of Ramos tumor (PG
0.01). RO1 analysis also detailed elevated radioactive uptakes
in the kidneys, liver, heart, and lungs, but low levels were
observed within soft tissue. After 20 h, HEC1A/EMP2 tumors
showed a 1.7-fold increase in 64Cu-DOTA-KS83 minibody
localization compared with the wild-type tumor (pG0.01) and a
5.4-fold increase in localization compared with Ramos tumors
(PG0.001). The difference between HEC1A and Ramos
Fig. 3. EMP2 internalizes in the presence of anti-EMP2
fragments. a Localization of anti-EMP2 antibody (KS83
diabody) fragment (using fluorescein-conjugated anti-Myc
antibody) on HEC1A/EMP2 after incubation for 10 min, 1 h,
and 24 h. b EMP2 localization detected by polyclonal anti-
EMP2 antibody (red) shows internalization in response 24 h
after incubation with anti-EMP2 (KS83 diabody). Isotype
control (A10 diabody) antibody fragments or no treatment
(control) shows no internalization of EMP2. 4′,6-Diamidino-2-
phenylindole was used for nuclear stain (blue).
Fig. 4. Conjugation of KS83 minibody with DOTA and
binding analysis of subsequent bioconjugates. a The
effect of varying the molar ratios of DOTA to KS83
minibody was determined by flow cytometry using
HEC1A/EMP2 cells. The optimal molar ratio of DOTA to
KS83 is 20:1, as shown by the best preserved binding
activity of the DOTA-KS83 bioconjugate to the cells. b
Representative flow cytometric image of HEC1A/EMP2
cells stained with unconjugated KS83 minibody and the
20:1 conjugated DOTA-KS83 minibody. Unconjugated
KS83 minibody and the isotype control A10 diabody are
depicted as the positive and negative controls, respec-
tively. c The level of binding of the KS83 and DOTA-KS83
minibody to human EMP2 second extracellular loop
peptide was determined by ELISA. Plates were coated
with the 24 amino acid human EMP2 peptide, and bound
minibodies were detected with HRP-conjugated goat anti-
human Fc-specific antibody.
74 M. Fu et al.: Feasibility of Imaging EMP2 in Endometrial Cancer
tumors was also significant as wild-type tumors showed
a 3.9-fold increase in radiolabeled KS83 localization (PG
0.05). In order to validate the ROI uptakes, tumors and
the major organs were excised from mice at either 4 or
20 h post-injection, and the activity in the organs was
counted in order to determine the percent injected dose
per gram (Table 2). The counts from ROI analysis and
ex vivo biodistribution were similar except that a slight
difference was observed in the kidney.
The data generated suggest that anti-EMP2 minibodies
localize specifically and with sensitivity to EMP2
positive tumors. However, an alternative possibility may
be that EMP2 positive tumors differ in their vascularity
and/or preferentially retain the radiometal labeled mini-
body. To explore the second possibility, experiments
were performed using a 64Cu-DOTA CD20 minibody on
HEC1A/EMP2 tumors. Table 3 compares the biodistri-
bution of the control isotype tracer with the KS83
minibody at time of killing (4 and 20 h). Anti-EMP2
minibodies showed a 1.2- and 3-fold increase in uptake
compared with radiolabeled anti-CD20 at 4 and 20 h,
respectively.
Fig. 5. Small-animal PET imaging of EMP2 using 64Cu-DOTA-KS83 minibody. a Small-animal PET coronal images of mice
bearing HEC1A/EMP2 (left shoulder, denoted white ellipse) and HEC1A (right shoulder, denoted yellow ellipse) tumor
xenografts following administration of 64Cu-labeled anti-EMP2 DOTA-KS83 minibody at 4 and 20 h. Bottom inset shows a
transverse image from the same animal. b Small-animal PET coronal images of mice bearing xenografts from HEC1A/EMP2
(left shoulder, denoted white ellipse) and Ramos (right shoulder, denoted red ellipse) cells. PET, CT, and PET/CT overlay images
are shown at 20 h time point. Bottom inset depicts a transverse image from the same animal. Images at both time points are
representative of five or more mice.
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Discussion
EMP2 is a tetraspan protein that is upregulated in a number of
gynecological cancers, including endometrial and ovarian [3,
13]. Using a large panel of mouse and human biospecimens,
we observed a restricted distribution of EMP2 protein
expression in normal tissues in both species, suggesting the
utility of EMP2 as a therapeutic and pharmacodiagnostic target.
While EMP2 expression in human tissues has been previously
studied, this has largely been evaluated at the level of
messenger RNA (mRNA) rather than protein expression;
however, the latter is most relevant to imaging strategies. In
the present study, we show that EMP2 protein expression is
largely concordant with mRNA expression, with EMP2 highly
expressed in alveolar epithelium of the lung [28, 29], in the
retinal pigmented epithelium in the eye [22], within secretory
endometrium [23, 30], and in epithelia of the vagina and
fallopian tube. In contrast, EMP2 was undetectable in many
human tissues, including the small and large intestines,
pancreas, liver, spleen, anovulatory endometrium, and kidney.
There is an unmet need for novel imaging strategies for
clinical management of endometrial and ovarian cancers. In
this paper, we show as a proof of principle that EMP2
expression can serve as a target for imaging. We have
previously shown that the KS83 diabody recognizes both
murine and human EMP2 and has therapeutic potential as
seen in a number of tumor models [3, 13]. We thus
hypothesized that imaging of EMP2 may serve as an early
monitor of response to tailored therapy or be useful prior to
surgical resection to identify metastatic disease. Therefore,
we reformatted the variable genes of the KS83 diabody [13]
into a minibody of approximately 80 kDa in size whose
pharmacokinetics and biodistribution are particularly favor-
able compared to other antibody fragments for tumor
imaging [21]. Minibodies have a slower clearance compared
to the diabody largely due to their increased molecular
weight, and they have been shown to be useful for PET
imaging [20].
Preliminary experiments showed that antibody fragment
binding to EMP2 caused the target to internalize. Indeed,
initial imaging studies using nonresidualizing anti-EMP2
antibody fragments (prepared with I-124 by the Iodogen
method) produced poor retention in the EMP2-positive
tumor xenografts (data not shown). This was not unexpected
as antigen internalization releases radioiodine by dehaloge-
nases either directly or after the protein is degraded to
iodotyrosines, resulting in loss of signal and low percent
injected dose per gram [36].
Accordingly, in this study, we prepared a residualizing
anti-EMP2 radiolabel using the bifunctional chelating agent
DOTA to conjugate minibody with a chelator for 64Cu [24,
37–39]. 64Cu-DOTA has been shown to have moderate
stability in vivo, which leads to a high hepatic radioactivity
uptake [40]. 64Cu-radiolabeled complexes with increased
stability have been studied with 1,4,8,11-tetraazacyclotetra-
decane-N,N′,N″,N′″-tetraacetic acid [40, 41], but this chela-
tor requires harsh reaction conditions such as elevated
temperature for complexation with the radiometal. Although
the 1,4,7-triazacyclononane-N,N′,N″-triacetic acid can be
labeled in mild conditions and provides better stability of
Cu-chelate complexes [42, 43], it has not been evaluated in
the clinic. Thus, in this study, we used DOTA-mono-N-
hydroxysuccinimide ester (DOTA-NHS-ester) conjugated
with lysine residues of KS83 minibody in order to radio-
metal label with 64Cu. Since lysine residues are present in
loops forming the antigen binding site, modification of the
lysine residues could potentially affect binding to the
antigen. Indeed, molar ratios of 50:1 and over greatly
impacted binding to EMP2 (Fig. 4a). However, a molar
ratio of 20:1 largely preserved the antigen binding activity
compared to unmodified KS83 minibody. Hence, this
conjugation strategy proved to be suitable for radiolabeling
the anti-EMP2 KS83 minibody.
Non-invasive serial PET imaging was used to generate data
in the same animal, providing important information of how the
compound moves through the body over time. Indeed, PET
images of tumor bearing mice injected with 64Cu-DOTA-KS83
minibody produced excellent radioactive uptake in EMP2-
positive tumors. At 20 h, which is the optimal time for minibody
imaging [37], drawn ROIs revealed 10.2±2.6%ID/g±SD in the
HEC1A/EMP2 tumor, a 5.4-fold uptake ratio compared to that
in the EMP2-negative tumor (1.9±0.5). These findings were
confirmed directly ex vivo by measuring the radioactivity in
excised organs.
Table 2. Estimated activities from drawn ROIs and uptakes measured
by ex vivo weighing and counting derived from 64Cu-DOTA-KS83 (n05)
Organ (%ID/g) ROI (4 h) ROI (20 h) Bio (4 h) Bio (20 h)
HEC1A/EMP2
tumor
7.6±1.2 10.2±2.6 7.3±0.5 9.7±1.9
Hec1A tumor 5.6±0.7 6.0±0.1 5.8±0.8 4.2±1.3
Ramos tumor 2.6±1.0 1.9±0.5 N.D. 2.3±0.5
Liver 19.6±1.9 19.6±3.5 19.2±5.4 18.1±1.6
Kidney 26.8±4.6 24.8±5.9 47.1±12.4 36.4±8.3
Lung 9.7±1.6 4.8±1.2 12.5±5.6 5.5±1.1
Heart 13.9±2.8 4.2±0.4 9.2±0.9 4.3±1.0
Soft tissue 0.7±0.2 0.7±0.2 1.0±0.4 0.8±0.1
Blood N.D. N.D. 18.1±3.0 3.7±0.6
Uterus N.D. N.D. 5.4±0.8 4.9±1.6
Data are expressed as %ID/g ± SD
N.D. not determined
Table 3. Biodistribution (bio) uptake of a control isotype tracer 64Cu-
DOTA-CD20 at time of killing (n02)
Organ (%ID/g) 4 h 20 h
Hec1A/EMP2 tumor 6.1±0.1 3.4±0.6
Liver 19.0±3.1 26.6±0.9
Kidney 33.1±8.6 24.2±8.2
Lung 12.1±2.6 6.2±0.9
Heart 8.3±2.1 6.2±0.7
Soft tissue 1.1±0.8 0.8±0.3
Blood 13.2±1.6 3.1±1.9
Uterus 5.6±2.7 4.9±0.6
Mean is measured with SD
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In order to determine the sensitivity of 64Cu-DOTA-
KS83 minibody to EMP2, xenografts were created using
both wild-type HEC1A and HEC1A/EMP2 cells. Published
reports have shown that there is a 2- to 4-fold increase in
EMP2 expression by Western blot analysis [8]. Imaging
with the 64Cu-DOTA-KS83 minibody demonstrated target-
ing to both HEC1A/EMP2 (10.2±2.6 % ID/g) and HEC1A
(6.0±0.1 % ID/g) tumors, with HEC1A/EMP2 exhibiting a
1.7-fold higher level of radioactivity compared to HEC1A
(PG0.01). Moreover, the high ratio of EMP2-positive tumor
relative to various normal tissues lacking EMP2 protein
expression (e.g., soft tissue, heart, blood) suggests that
EMP2 minibodies specifically and efficiently adhere to their
antigen. To verify that the retention was not due to
permeability and retention effects, HEC1A/EMP2 xenografts
were targeted using a control isotype tracer. Injections with
radiometal-labeled anti-CD20 minibody showed low levels
of tracer within the tumor, suggesting that the high radio-
uptake of labeled EMP2 minibody was specific.
Of note, high radioactive uptake of 64Cu-DOTA-KS83
minibody was observed in liver and kidney even though
these are not sites of EMP2 expression. This uptake may be
attributed in part to the minibody or the radiometal itself.
The liver uptake was expected, due to the size of the
minibody that is above the renal threshold for clearance
(960 kDa) and possibly by avid transchelation of the
radiometal 64Cu [40]. The elevated renal uptake was
unexpected, but may reflect the small fraction of partially
metabolized 64Cu-DOTA-KS83 minibody, which despite
residualizing properties are released into circulation from
primary tissue binding sites and reach the kidney where the
partially metabolized products may be retained. This may
also explain the slightly elevated levels of agent detectable at
20 h in the blood and heart (the latter largely reflecting a
blood compartment signal). Consistent with this explanation,
high radioactive uptake was also observed using the 64Cu-
DOTA-CD20 minibody.
The present and previous studies show that EMP2 is
highly expressed in normal lung (type 1 pneumocytes) [44].
As the minibody recognizes both human and murine EMP2,
it is notable that lung uptake of 64Cu-DOTA-KS83 minibody
is G2-fold higher than the activity in the blood. This suggests
that EMP2 in native pulmonary epithelium may be relatively
sequestered from access to 64Cu-DOTA-KS83 minibody.
Consistent with this hypothesis, localization of EMP2 in
polarized epithelia is restricted to zona adherens (Morales
and Gordon, unpublished data). Nonetheless, the expression
of EMP2 may make it difficult to detect and characterize
lung metastases. Additional experiments will be needed to
verify these and other utilities.
In conclusion, EMP2 is novel cancer biomarker, notably
for endometrial and ovarian cancer, that has been previously
shown to be an independent prognostic indicator, and an
effective target in preclinical recombinant antibody therapy.
In this study, we characterize a residualizing imaging agent,
a 64Cu-labeled minibody to EMP2, and demonstrate its
effectiveness in imaging human EMP2-positive endometrial
tumor xenografts. We predict that with further refinement
anti-EMP2 antibody fragments may be have value for
imaging of tumor localization and therapeutic response in
patients with EMP2-positive malignancies.
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